HHS Secretary Alex Azar said Friday (Feb. 1) it would make even more sense for pharmacy benefit managers to negotiate prices for Part B drugs if rebates were eliminated. “If Congress were to move B into D, or parts of B into D, I think it makes that D option just all that more attractive,” Azar said. Subjecting Part B drugs to price negotiations in Part D used to be Azar’s top drug-pricing policy priority , and he had planned...